Life Sciences and the Valley of Death

The ‘Valley of Death’ is a term coined for the period between U.S. Food and Drug Administration (FDA) approval and before payers (public and private) have either devised a payment methodology or made the decision to provide coverage for and price the product. Differences in standards between FDA approval and Medicare program coverage result from divergent statutory standards.
AEI’s Brian J. Miller will host a group of experts to discuss the differences between these standards, recent policy actions that undermine confidence in certain therapies and exacerbate the Valley of Death, and steps that regulators and lawmakers can take to close the gap without undermining each agency’s distinct mission.
Subscribe to AEI's TH-cam Channel
th-cam.com/users/AEIVideo...
Like us on Facebook
/ aeionline
Follow us on Twitter
/ aei
For more information
www.aei.org
AEI operates independently of any political party and does not take institutional positions on any issues. AEI scholars, fellows, and their guests frequently take positions on policy and other issues. When they do, they speak for themselves and not for AEI or its trustees or other scholars or employees.
More information on AEI research integrity can be found here: www.aei.org/about/
#aei #news #politics #government #education #livestream #live #biologics #healthcarepolicy

[@user-zi8ht1fi6c]

Why is zogbot here?